Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss which populations are seen as the most underrepresented in oncology clinical trials.

The California wildfires severely affected patients with cancer, requiring evacuation protocols, community support, and ...

The FDA has granted a 510 (k) clearance to the Ibex Prostate Detect software (formerly Galen Second Read). The Ibex Prostate ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.

Negative language about patients can reduce clinician empathy and recall of critical health details, a recent study finds.

The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular ...

ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

Panelists discuss how myelofibrosis can evolve following initial treatment, examining common patterns of disease progression and strategies for adapting therapeutic approaches based on individual ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.